| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2001;37:1388.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Effects of an Angiotensin-Converting Enzyme Inhibitor and a ß-Blocker on Cerebral Arteriolar Dilatation in Hypertensive Rats
From the Cardiovascular Research Group, Faculty of Pharmacy, University of Nancy (J.-M.C.), Nancy, France; and Department of Pathology, University of Iowa College of Medicine and Cardiovascular Center (G.L.B.), Iowa City.
Correspondence to Jean-Marc Chillon, PhD, Laboratoire de Pharmacologie Cardiovasculaire, Faculté de Pharmacie, UHP-Nancy 1, 5 rue Albert Lebrun, BP 403, 54001 Nancy Cedex, France. E-mail chillon{at}pharma.u-nancy.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—We examined the effects of the angiotensin-converting enzyme inhibitor perindopril and the ß-blocker propranolol on dilator responses of cerebral arterioles in chronic hypertension. Dilator responses to acute hypotension were examined in untreated Wistar-Kyoto rats (WKY) and stroke-prone spontaneously hypertensive rats (SHRSP) that were untreated or treated for 3 months with a low (0.3 mg · kg-1 · day-1) or a high (2 mg · kg-1 · day-1) dose of perindopril or a dose of propranolol (250 mg · kg-1 · day-1) alone or in combination with the low dose of perindopril. Pressure (servo-null) and diameter were measured in cerebral arterioles during acute reductions in arterial pressure both before and during maximal dilatation (EDTA). The high dose of perindopril or the combination of propranolol and perindopril normalized cerebral arteriolar pressure (52±2 [mean±SEM], 49±2 mm Hg versus 50±2 mm Hg in WKY and 96±3 mm Hg in untreated SHRSP; P<0.05). In contrast, the low dose of perindopril or propranolol alone did not normalize arteriolar pressure (74±2 mm Hg and 58±3 mm Hg). Both the low and high doses of perindopril improved autoregulatory dilatation, maximal dilatation, and dilator reserve of cerebral arterioles in SHRSP, with the low dose of perindopril being almost as effective as the high dose of perindopril. Propranolol alone did not significantly improve dilator function of cerebral arterioles. Furthermore, dilator function of cerebral arterioles was not further improved by the addition of propranolol to the low dose of perindopril. These findings suggest that angiotensin-converting enzyme inhibitors, such as perindopril, may be more effective than propranolol in attenuating the impairment of cerebral autoregulatory vasodilatation, maximal dilatation, and dilator reserve during treatment of chronic hypertension.
Key Words: hypertension, chronic • angiotensin • autoregulation • dilatation • remodeling • hypertrophy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Chronic hypertension impairs dilator responses of cerebral blood vessels to both submaximal1 2 and maximal stimuli.3 One of the explanations for altered vascular responsiveness is that hypertrophy of the vessel wall encroaches on the vascular lumen and reduces internal diameter.4 5 6 Another explanation that has been proposed for encroachment and reduced internal diameter is that "remodeling" occurs in cerebral blood vessels during chronic hypertension. In the context of chronic hypertension, we define remodeling as a reduction in external diameter of the vessels that is not produced by reduction in vascular compliance.3
We have speculated that impaired responses of cerebral blood vessels to submaximal dilator stimuli may be linked to impairment of maximal dilator capacity.7 It is far from clear, however, whether such a link exists. A first step toward examining this question would be to prevent or attenuate reductions in maximal dilator capacity of cerebral blood vessels during chronic hypertension and then determine whether dilator responses to submaximal dilator stimuli are improved. In a recent study,8 we found that treatment of stroke-prone spontaneously hypertensive rats (SHRSP) with the ACE inhibitor perindopril attenuated reductions in maximal dilatation of cerebral arterioles. In contrast, treatment of SHRSP with the ß-blocker propranolol did not significantly attenuate reductions in maximal dilatation of cerebral arterioles.
We therefore undertook the present study to examine the possibility that treatment of SHRSP with perindopril, but not propranolol, may improve responses of cerebral arterioles to a submaximal dilator stimuli. We chose acute hypotension as the submaximal dilator stimulus because cerebral arteriolar dilatation in response to acute hypotension is a critical parameter of cerebral vascular autoregulation. A possible risk concerning vascular autoregulation during the treatment of hypertension is that a treatment that effectively lowers pressure without restoring dilator capacity may increase the potential susceptibility to cerebral ischemia, particularly if the treatment increases the likelihood of acute hypotension episodes.
Five groups of SHRSP were examined: (1) an untreated group, (2) a group treated with a high dose of perindopril, (3) a group treated with a low dose of perindopril, (4) a group treated with the ß-blocker propranolol, and (5) a group treated with a combination of propranolol and a low dose of perindopril. On the basis of the results obtained in the previous experiment,8 we anticipated that if maximal dilator capacity influences the responses of cerebral arterioles to submaximal dilator stimuli, treatment of SHRSP with both the low and high doses of perindopril, but not propranolol, would attenuate impaired responses of cerebral arterioles to acute hypotension.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experiments were conducted on male Wistar-Kyoto rats (WKY) and male SHRSP. SHRSP and WKY were obtained from a well-established inbred colony that is maintained in the University of Iowa Animal Care Facility. At 3 months of age, the SHRSP were divided into 5 groups: (1) an untreated group (n=11) that drank tap water, (2) a group (n=7) that received a low dose of perindopril (0.3 mg/kg), (3) a group (n=8) that received a high dose of perindopril (2 mg/kg), (4) a group (n=9) that received propranolol alone (250 mg/kg), and (5) a group (n=7) that received a combination of the low dose of perindopril (0.3 mg/kg) plus propranolol (250 mg/kg). The doses of perindopril and propranolol were chosen according to the previous study.8 In the first study, the high dose of perindopril was chosen to normalize blood pressure in hypertensive rats in accordance to information from Servier Laboratories and an earlier study.9 The low dose of perindopril was chosen to have minimal impact on blood pressure. The dose of propranolol was chosen to decrease systemic pressure in SHRSP as effectively as the high dose of perindopril. Systolic blood pressure was measured weekly in all rats during the first month of the experiment and every 2 weeks thereafter by the tail-cuff method (results not shown). Perindopril and propranolol were administered in the drinking water. WKY that drank tap water were used as normotensive controls (n=10). Animals were allowed free access to food and water, housed at 25°C, and exposed to 12 hours of light each day. Procedures followed in this study were in accordance with the institutional guidelines set forth by the University of Iowa.
After 3 months of treatment, we examined the active and passive responses of cerebral arterioles using a surgery similar to the one used in our previous experiment.8
Measurement of Cerebral Arteriolar Pressure
and Diameter
Pressure and internal diameter were measured in
first-order arterioles on the surface of the
cerebrum10 through an
open-skull preparation as previously
described.8 11
After making a craniotomy over the left parietal
cortex, the exposed brain was continuously suffused with artificial
cerebral spinal fluid (CSF), warmed to 37°C to 38°C, and
equilibrated with a gas mixture of 5% CO2/95%
N2. Pressure was measured continuously in
cerebral arterioles with a micropipette connected to a servo-null
pressure-measuring device (model 5, Instrumentation for Physiology and
Medicine, Inc). Arterioles were monitored through a Leitz microscope
(NPI x10 objective) connected to a closed-circuit video system with a
final magnification of x356. Images of arterioles were digitized using
a Macintosh computer (Quadra 900, Apple Computer). Arteriolar diameter
was measured from the digitized images by the use of image
analysis software (NIH Image, National Institutes of Health,
Research Services Branch, National Institute of Mental
Health).
Experimental Protocol
Approximately 20 to 30 minutes after completion of
surgery, measurements of cerebral arterioles were obtained under
baseline conditions. To examine active responses, pressure-internal
diameter relationships were obtained in cerebral arterioles between
cerebral arteriolar pressures of 60 and 10 mm Hg.
Hemorrhage was used to reduce cerebral arteriolar pressure in
decrements of 10 mm Hg at pressures down to 20 mm Hg of
cerebral arteriolar pressure and decrements of 5 mm Hg at
pressures between 20 and 10 mm Hg. Arterial blood
gases in all groups of animals remained within normal limits during all
manipulations before deactivation of cerebral arterioles
(Table).
|
To examine passive responses, pressure-internal diameter measurements were repeated in cerebral arterioles during maximal dilatation. Maximal dilatation was obtained by suffusing cerebral vessels with artificial CSF that contained EDTA (67 mmol/L), which produces complete deactivation of smooth muscle in cerebral arterioles.11 At the end of each experiment, the animal was killed by an injection of anesthetic.
Statistical Analysis
ANOVA was used to compare systemic pressure,
arteriolar pressure, and diameters. The probability values were
calculated with a Student’s t
test. Statistics were determined using the JMP statistics software (SAS
Institute Inc) on a Macintosh
computer.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline Values
Systemic arterial pressure and cerebral arteriolar pressure were significantly greater in untreated 6-month-old SHRSP than in age-matched WKY (Table). The low dose of perindopril reduced systemic arterial pressure and cerebral arteriolar pressure in SHRSP to a level approximately halfway between untreated SHRSP and WKY, whereas the high dose of perindopril nearly normalized systemic arterial pressure and completely normalized cerebral arteriolar pressure (Table). Although propranolol alone did not reduce systemic arterial pressure and cerebral arteriolar pressure in SHRSP as effectively as the high dose of perindopril, it was significantly more effective than the low dose of perindopril (Table). Combining the low dose of perindopril with propranolol fully normalized systemic arterial pressure and cerebral arteriolar pressure in SHRSP (Table).
Before the deactivation of cerebral arterioles with EDTA, the diameter of the cerebral arterioles was significantly less in untreated SHRSP than in WKY (Table). Treatment of SHRSP with the low and high doses of perindopril, as well as propranolol alone and combined with the low dose of perindopril, significantly increased cerebral arteriolar diameter (Table). Diameters were significantly less, however, in all of the treatment groups than in WKY.
After deactivation, the diameter of the cerebral arterioles was significantly smaller in untreated SHRSP than in WKY (Table). Diameter was significantly greater in SHRSP treated with both the low and high doses of perindopril than in untreated SHRSP. In contrast, diameter was not significantly increased in SHRSP treated with propranolol alone. Propranolol combined with the low dose of perindopril, on the other hand, significantly increased the diameter in SHRSP.
Active and Passive Responses
The pressure-diameter relationship before deactivation
of vascular smooth muscle with EDTA was shifted to a lower level in the
cerebral arterioles of untreated SHRSP than WKY
(Figure 1, left). Although the difference in diameters
between the 2 groups became less at lower levels of arteriolar
pressure, the diameter remained significantly decreased in untreated
SHRSP, even at arteriolar pressures of 10 to 20 mm Hg. Treatment
of SHRSP with the low
(Figure 1, right) and high
(Figure 1, left) doses of perindopril resulted in a
significant upward shift of the pressure-diameter relationship at all
levels of arteriolar pressure. The relationship in both groups of
treated SHRSP, however, remained reduced relative to WKY. Treatment of
SHRSP with propranolol alone significantly shifted the
pressure-diameter relationship upward at arteriolar pressures of
30 mm Hg and higher
(Figure 1, left). At arteriolar pressures of 20 mm Hg
and lower, diameters were similar in SHRSP treated with
propranolol alone and untreated SHRSP. The addition of
propranolol to the low dose of perindopril resulted in no
further shift in the pressure-diameter relationship in the cerebral
arterioles of SHRSP
(Figure 1, right).
|
, n=10, left) and SHRSP that were untreated (
, n=11, left) or treated with the high dose of perindopril (Per-H, •, n=8, left) or propranolol alone (Prop, 
, n=9, left) and in SHRSP that were treated with the low dose of perindopril (Per-L, 
, n=7, right) or the combination of propranolol plus the low dose of perindopril (
, n=7, right). Measurements were obtained before maximal dilatation with EDTA. Values are mean±SEM. *P<0.05 vs WKY; 
P<0.05 vs SHRSP.During maximal dilatation of cerebral arterioles with EDTA, the diameter was significantly less in SHRSP than in WKY at all levels of cerebral arteriolar pressure between 60 mm Hg and 10 mm Hg (Figure 2, left). Both the low (Figure 2, right) and high (Figure 2, left) doses of perindopril significantly increased, but did not fully normalize, the diameter of cerebral arterioles in SHRSP at all levels of arteriolar pressure. Propranolol alone, on the other hand, did not significantly increase diameter at any level of pressure (Figure 2, left). Furthermore, the addition of propranolol to the low dose of perindopril resulted in no further increase in diameter (Figure 2, right).
|
Dilator reserve, which was defined as the difference in the diameter of the cerebral arterioles before and after maximal dilatation, was significantly less in untreated SHRSP than WKY at arteriolar pressures of 15 mm Hg and higher. Treatment of SHRSP with either the low (Figure 3, right) or high (Figure 3, left) doses of perindopril completely normalized dilator reserve of cerebral arterioles. In contrast, treatment with propranolol alone had little effect on dilator reserve at arteriolar pressures <40 mm Hg (Figure 3, left). In addition, combining propranolol with the low dose of perindopril did not result in further improvement of dilator reserve (Figure 3, right).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
There were 2 major findings in this study. First, treatment with both the high and low dose of perindopril improved submaximal dilator responses to acute reductions in pressure in cerebral arterioles of SHRSP. Propranolol, on the other hand, improved autoregulatory dilatation of cerebral arterioles less effectively than perindopril. Second, both the low and high doses of perindopril improved maximal dilator responses of cerebral arterioles in SHRSP. In contrast, propranolol was less effective than perindopril in improving maximal dilator responses of cerebral arterioles.
We undertook the present study to examine the possibility that the treatment of SHRSP with perindopril, but not propranolol, may improve responses of cerebral arterioles to a submaximal dilator stimuli as it did for responses to a maximal dilator stimuli.8 It is indeed tempting to speculate that the impairment of maximal dilatation may be a major contributor to reduced responses of cerebral vessels to submaximal dilator stimuli during chronic hypertension.12 The explanation for alterations in vascular responsiveness that has been most widely recognized is that hypertrophy of the vessel wall encroaches on the vascular lumen.4 5 6 Another explanation that has been proposed for encroachment on the lumen, and hence altered vascular responsiveness, is that "remodeling" occurs in cerebral blood vessels during chronic hypertension.3 We define remodeling in the context of chronic hypertension as a reduction in the external diameter of the vessels that is not produced by reduction in vascular compliance. Remember, however, that although structural changes in blood vessels interfere with maximal vasodilator responses during hypertension, it is not clear whether these changes contribute significantly to impaired responses to submaximal dilator stimuli. This unanswered question is quite important because submaximal dilator stimuli, such as acute hypotension, occur far more frequently than maximal dilator stimuli.
Results from the present study combined with our previous study8 suggest that the mechanism that underlies the effects of perindopril on autoregulatory dilatation and dilator reserve in cerebral arterioles of SHRSP may be related, at least in part, to its effects on remodeling. We found previously that perindopril in either a low or a high dose attenuated remodeling of cerebral arterioles in SHRSP, whereas propranolol did not.8 In the present study, both the low and high doses of perindopril, but not propranolol, improved submaximal and maximal dilator responses to acute reductions in pressure. Thus, the pattern of effects of treatment on remodeling of cerebral arterioles in SHRSP closely correlates with the pattern of effects of treatment on autoregulatory dilatation. If no correlation had been found between remodeling and autoregulatory dilatation of cerebral arterioles in SHRSP, we would be able to state with reasonable certainty that structural alterations in cerebral arterioles of SHRSP do not contribute to their impaired responses to submaximal dilator stimuli. The corollary, however, is not necessarily true. The correlation we found between attenuation of remodeling and impaired autoregulatory dilatation in cerebral arterioles of SHRSP does not in and of itself confer a cause-and-effect relationship between remodeling and impaired autoregulatory dilatation. At least 2 other factors may have contributed to the improvement of submaximal dilator responses to acute reductions in pressure in cerebral arterioles of SHRSP treated with perindopril, independent of perindopril’s effect on remodeling.
One alternative is that ACE inhibitors dilate larger, but not smaller, cerebral arteries, which in turn leads to a compensatory autoregulatory constriction of smaller arteries downstream to counteract increases in cerebral blood flow that would otherwise occur. This autoregulatory constriction would in effect result in an apparent increase in the dilator reserve. This possibility is supported by the proposal that the constriction of cerebral blood vessels by the renin-angiotensin system is confined primarily to larger cerebral arteries and, thus, only larger cerebral arteries dilate during inhibition of ACE.13 14 15 This hypothesis, however, is not supported by our finding in this study that the diameter of cerebral arterioles under baseline conditions was larger, rather than smaller, in SHRSP treated with perindopril than in untreated SHRSP.
Another alternative to remodeling is that ACE inhibitors improve endothelium-dependent dilatation in hypertensive rats16 17 and humans.18 19 In contrast, ß-blockers do not improve endothelium-dependent relaxation in hypertensive subjects,20 21 except for new generation ß-blockers, such as carvedilol, that scavenge free radicals.19 22 Several studies suggest that endothelial factors may play a role in cerebral autoregulation.23 24 Thus, by improving endothelium-dependent dilatation, ACE inhibitors may improve autoregulatory dilatation. However, we suggest caution with respect to this interpretation because others have reported that endothelial factors do not influence cerebral autoregulation.25 26
The findings in this study and our previous study8 also may be relevant to the question of whether remodeling or hypertrophy is more important to impaired dilatation of cerebral arterioles in SHRSP. On the basis of calculations from measurements made in maximally dilated cerebral arterioles in WKY and SHRSP, we have speculated that remodeling contributes substantially more to impaired maximal dilatation than hypertrophy.3 In this study, we found that the low dose of perindopril improved autoregulatory dilatation, maximal dilatation, and dilator reserve of cerebral arterioles in SHRSP almost as effectively as the high dose. In a previous study, we have shown that both the low and high doses of perindopril significantly attenuate remodeling whereas only the high dose prevents arteriolar wall hypertrophy.8 The combination of these findings support the hypothesis that remodeling may play a greater role than hypertrophy in the impairment of cerebral arteriolar dilatation.
Conclusion
We conclude that antihypertensive treatment with
perindopril attenuates reductions in autoregulatory dilatation, maximal
dilator capacity, and dilator reserve in cerebral arterioles. In
addition to its effects on cerebral arteriolar dilatation, perindopril
also attenuates remodeling of cerebral arterioles. It is of particular
interest that perindopril improves dilator function and attenuates
remodeling, even in a dose that only partially normalizes arteriolar
pressure and fails to prevent hypertrophy. Antihypertensive
treatment with propranolol, on the other hand, does not
attenuate reductions in cerebral arteriolar dilatation or remodeling,
even in a dose that lowers arteriolar pressure more effectively than
the low dose of perindopril. We cannot rule out the possibility that a
higher dose of propranolol than was used in this study
might have had greater effects on remodeling, hypertrophy,
and autoregulatory dilatation. We think this outcome is unlikely,
however, because a relatively high dose of propranolol was
required in this study to decrease blood pressure in SHRSP as
effectively as the high dose of perindopril. Furthermore, any
additional effects that might have been observed with doses of
propranolol significantly higher than the dose used in this
study may have been difficult to interpret because of potential
nonspecific effects of propranolol unrelated to its
ß-blocker activity.
The finding in this study that the ACE inhibitor perindopril was more effective than propranolol in restoring cerebral arteriolar dilatation may have important implications with respect to cerebral ischemia. Impairment of vasodilator responses by chronic hypertension can presumably cause cerebral ischemia during acute episodes of hypotension, because cerebral vessels may not be able to dilate sufficiently to meet tissue needs. Thus, the restoration of cerebral vasodilator capacity to prehypertensive levels with an ACE inhibitor may help to prevent cerebral ischemia during the treatment of chronic hypertension by enabling the cerebral circulation to respond more effectively to vasodilator stimuli.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grants HL-22149, NS-24621, and HL94-006; funds from the Iowa Affiliate of the American Heart Association; and funds from the Institut de Recherches Internationales Servier. Jean-Marc Chillon was the recipient of a Fellowship Award from the Iowa Affiliate of the American Heart Association at the time this work was performed.
Received October 4, 2000; first decision October 24, 2000; accepted November 1, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Fujishima M, Sadoshima S, Ogata J, Yoshida F, Shiokawa O, Ibayashi S, Omae T. Autoregulation of cerebral blood flow in young and aged spontaneously hypertensive rats (SHR). Gerontology. 1984;30:30–36.[Medline] [Order article via Infotrieve]
2.
Jones JV, Fitch W,
McKenzie ET, Strandgaard S, Harper AM. Lower limit of cerebral blood
flow autoregulation in experimental renovascular hypertension in the
baboon. Circ Res. 1976;39:555–557.
3.
Baumbach GL,
Heistad DD. Remodeling of cerebral arterioles in chronic hypertension.
Hypertension. 1989;13:968–972.
4. Folkow B, Hallbäck M, Lundgren Y, Sivertsson R, Weiss L. Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res. 1973;32(suppl I):I-2–I-16.
5. Folkow B, Grimby G, Thulesius O. Adaptative structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Sand. 1958;44:255–272.
6. Folkow B. Cardiovascular structural adaptation: its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med Suppl. 1978;4:3s–22s.[Medline] [Order article via Infotrieve]
7. Baumbach GL, Heistad DD. Cerebrovascular disease in experimental models of hypertension. In: Swales J, ed. Textbook of Hypertension. Oxford, England: Blackwell Scientific; 1993:682–690.
8.
Chillon JM,
Baumbach GL. Effects of an angiotensin-converting enzyme
inhibitor and a ß-blocker on cerebral arterioles in rats.
Hypertension. 1999;33:856–861.
9. Unger T, Moursi M, Ganten D, Hermann K, Lang RE. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490–3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (HOE498). J Cardiovasc Pharmacol. 1986;8:276–285.[Medline] [Order article via Infotrieve]
10.
Harper SL, Bohlen
HG. Microvascular adaptation in the cerebral cortex of adult
spontaneously hypertensive rats.
Hypertension. 1984;6:408–419.
11.
Baumbach GL,
Dobrin PB, Hart MN, Heistad DD. Mechanics of cerebral arterioles in
hypertensive rats. Circ Res. 1988;62:56–64.
12.
Fujii K, Heistad
DD, Faraci FM. Flow-mediated dilation of the basilar artery in vivo.
Circ Res. 1991;69:697–705.
13. Bouthier J, Safar ME, Benetos A, Simon AC, Levenson J, Hugues CM. Haemodynamic effects of vasodilating drugs on the common carotid and brachial circulations of patients with essential hypertension. Br J Clin Pharmacol. 1986;21:137–142.[Medline] [Order article via Infotrieve]
14. Postiglione A, Bobkiewicz T, Vinholdt-Pedersen E, Lassen NA, Paulson OB, Barry DI. Cerebrovascular effects of angiotensin converting enzyme inhibition involve large artery dilatation in rats. Stroke. 1991; 22: 1363–1368.
15. Whalley ET, Wahl M. Cerebrovascular reactivity to angiotensin and angiotensin-converting enzyme activity in cerebrospinal fluid. Brain Res. 1988;438:1–7.[Medline] [Order article via Infotrieve]
16.
Yang ST, Faraci
FM, Heistad DD. Effects of cilazapril on cerebral vasodilatation in
hypertensive rats.
Hypertension. 1993;22:150–155.
17.
Clozel M, Kuhn H,
Hefti F. Effects of angiotensin-converting enzyme
inhibitors and of hydralazine on
endothelial function in hypertensive rats.
Hypertension. 1990;16:532–540.
18. Millgård J, Hägg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens. 1998;12:511–516.[Medline] [Order article via Infotrieve]
19. Schiffrin EL. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J Suppl. 1998;47:15–21.[Medline] [Order article via Infotrieve]
20.
Higashi Y, Sasaki
S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G,
Oshima T. A comparison of angiotensin-converting enzyme
inhibitors, calcium antagonists, beta-blockers
and diuretic agents on reactive hyperemia in patients
with essential hypertension: a multicenter study.
J Am Coll Cardiol. 2000;35:284–291.
21. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens. 1996;14:1247–1255.[Medline] [Order article via Infotrieve]
22.
Yue TL,
McKenna PJ, Gu JL, Cheng HY, Ruffolo REJ, Feuerstein GZ. Carvedilol, a
new vasodilating beta adrenoceptor blocker antihypertensive drug,
protects endothelial cells from damage initiated by
xanthine-xanthine oxidase and neutrophils.
Cardiovasc Res. 1994;28:400–406.
23. Jones SC, Radinsky CR, Furlan AJ, Chyatte D, Perez-Trepichio AD. Cortical NOS inhibition raises the lower limit of cerebral blood flow-arterial pressure autoregulation. Am J Physiol. 1999;276(pt 2):H1253–H1262.
24. Kobari M, Fukuuchi Y, Tomita M, Tanahashi N, Takeda H. Role of nitric oxide in regulation of cerebral microvascular tone and regulation of cerebral blood flow in cats. Brain Res. 1994;667:255–262.[Medline] [Order article via Infotrieve]
25. Faraci FM, Baumbach GL, Heistad DD. Myogenic mechanisms in the cerebral circulation. J Hypertens. 1989;7(suppl 4):S61–S64.
26. Takahashi S, Cook M, Jehle J, Kennedy C, Sokoloff L. Preservation of autoregulatory cerebral vasodilator responses to hypotension after inhibition of nitric oxide synthesis. Brain Res. 1995;678:21–28. [Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. R. Jennings, M. F. Muldoon, J. Price, I. C. Christie, and C. C. Meltzer Cerebrovascular Support for Cognitive Processing in Hypertensive Patients Is Altered by Blood Pressure Treatment Hypertension, July 1, 2008; 52(1): 65 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hatazawa, E. Shimosegawa, Y. Osaki, M. Ibaraki, N. Oku, S. Hasegawa, K. Nagata, Y. Hirata, and Y. Miura Long-Term Angiotensin-Converting Enzyme Inhibitor Perindopril Therapy Improves Cerebral Perfusion Reserve in Patients With Previous Minor Stroke Stroke, September 1, 2004; 35(9): 2117 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Chillon and G. L. Baumbach Effects of Indapamide, a Thiazide-Like Diuretic, on Structure of Cerebral Arterioles in Hypertensive Rats Hypertension, May 1, 2004; 43(5): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Iadecola and P. B. Gorelick Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure Stroke, February 1, 2004; 35(2): 348 - 350. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Baumbach, C. D. Sigmund, and F. M. Faraci Cerebral Arteriolar Structure in Mice Overexpressing Human Renin and Angiotensinogen Hypertension, January 1, 2003; 41(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ito, H. Yamakawa, C. Bregonzio, J. A. Terron, A. Falcon-Neri, and J. M. Saavedra Protection Against Ischemia and Improvement of Cerebral Blood Flow in Genetically Hypertensive Rats by Chronic Pretreatment With an Angiotensin II AT1 Antagonist Stroke, September 1, 2002; 33(9): 2297 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Mulvany Small Artery Remodeling and Significance in the Development of Hypertension Physiology, June 1, 2002; 17(3): 105 - 109. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||